** Shares of drugmaker Rigel Pharmaceuticals RIGL.O rise ~3% to $19.54
** RIGL says it has settled patent litigation with Annora Pharma regarding co's blood disorder drug, Tavalisse, to treat patients with immune thrombocytopenia $(ITP)$ who haven't responded adequately to prior treatments
** Lawsuit began when Annora submitted an application to the FDA to market a generic version of Tavalisse
** ITP is a condition where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding
** Under the settlement, Annora will be allowed to sell its generic version starting in Q2 2032 or earlier under certain circumstances
** Annora did not immediately respond to Reuters' request for comment
** RIGL gained 33.6% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.